Real-world data show that adjuvant therapy, not complete nodal dissection, is crucial for preventing relapse in patients with ...

A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not ...